Novocure

Profile narrative

Novocure is a publicly traded medical technology and oncology company headquartered in Switzerland. The company concentrates on the research, development, and commercialization of therapies for cancer patients. Its flagship technology is tumor treating fields (TTFields), a non‑invasive approach that uses electric fields to disrupt cancer cell division. TTFields‑based systems are designed for the treatment of various solid tumors and are intended to be used alongside standard oncologic care. Novocure markets its products to healthcare providers and treats patients in multiple geographic regions, reflecting a global commercial footprint. The company’s offerings are regulated medical devices that have received clearance from authorities such as the U.S. Food and Drug Administration and CE marking in Europe.

While specific quantitative measures of size or employee count are not disclosed in the supplied material, the company’s status as a publicly traded entity indicates it is subject to standard financial reporting and governance requirements. A distinguishing attribute of Novocure is its specialization in TTFields, which sets it apart from conventional pharmacological or radiation‑based cancer treatments. The company has demonstrated notable competency in navigating regulatory pathways to obtain approvals for its devices in major markets. Structurally, Novocure operates through a network of subsidiaries; the August 2026 incident originated from one of its subsidiaries, prompting an internal investigation and external forensic support. No parent organization is mentioned in the available information, indicating that Novocure functions as an independent publicly traded company. The breach incident, which exposed limited patient identifiers and contact information, underscores the importance of robust cybersecurity controls even for organizations whose primary impact is in the medical device sector.

Incidents

1 incident linked to this organisation.